ATRA - Mergers and acquisitions

TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for USD 100 million. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies' global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). The 90,000 sq. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies inc

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing facility in Thousand Oaks, California for USD 100 million upfront and the commencement of a long-term strategic supply agreement. This partnership and acquisition was first announced in January 2022. With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexib